Study of a new pneumococcal vaccine for infants and toddlers
Treatments studied
Part of Infections clinical trials.
This trial tests a new vaccine called V118C to protect children against pneumococcal disease. It is for two age groups: toddlers aged 12-15 months who already had 3 doses of a standard pneumococcal vaccine, and babies about 2 months old who have not had any pneumococcal vaccine yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For toddlers: must be 12 to 15 months old and have had 3 doses of the PCV20 vaccine as a baby.
- For babies: must be about 2 months old and never received any pneumococcal vaccine before.
- Your child must have been born full term (at least 37 weeks of pregnancy).
- Your child must not have ever had invasive pneumococcal disease (a serious infection).
- Your child must not be allergic to any ingredient in the study vaccines or diphtheria toxoid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
This study tests a new pneumococcal vaccine (PCV24) for babies ages 2 to 23 months. It aims to see if the vaccine is safe and helps protect against serious infections like pneumonia and meningitis.
This study tests a new vaccine that protects against 21 types of bacteria that cause pneumonia and other infections. It is for healthy infants around 2 months old to see if it works as well as the current vaccine.
This trial tests a new vaccine designed to protect against 24 types of pneumococcal bacteria (which cause pneumonia and other serious infections). Researchers are checking if it's safe and how well it works in infants, children, and adults.
This trial tests a new pneumococcal vaccine (PCV24) in healthy infants and children. It aims to protect against serious infections like pneumonia and meningitis caused by pneumococcal bacteria.
Hear when a new Pneumococcal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.